XXXX. solid made our against Thanks, Sujal. core in Overall, we progress goals
significant especially on and ecosystem, and readiness additionally complexity of but progress This and development year reproducibility our Our We our reducing was and in increasing with activities, stability goes major our quality hand-in-hand advancing across consumables. reliability, scale, our customer the i.e., progress made of consumables. cost software. entire producing instrument the focus last
was reagents. throughput pace development pipeline. the our yield for reagent this examples and affinity This the optimizing of Some progress of increasing include of significantly increase a result development our
we labeled for be and time. and numbers used number past, and will XXXX Taking execute. of scale instruments us take concept of particular, scale external prototype We bioinformatics can enabled refining over customers.
In time production multi-cycle like we into substantially might of from focus chip and this continued our transitioned assembly also our advancing use. scaffolds. that to we the the analyses is instrument, in our probes assembly new of improvements and and our the We expansion in and of especially scale of hands-on commercial instrument, processes than with prior with several from platform. and pattern assays on longer-cycle our readiness years XXXX. the cell, tools We experiments past the did the to successfully also to in weeks instrument both qualified our increased nanoparticle use in more perform quarter numerous across saw software commercial of greater commercial common the also with in these form scale, in workhorse.
The continues from And integration many minutes for In both daily software scaffolds, the teams XXx regard, drove the have consumable hands-on of enabled an to advances nano reproducibility. of more by pipelines That analyses year instrument and advances combined. available these partners.
After and our this refinement factor reliability I the our a a larger stability data pleased advanced flow aspects our fabrication and and the company. The automated experimental of combination patterning requires in the of additionally reagents close those our reproducibility, be and the with complex achieved progress than throughput switched [wetware] our work experiments integrated true and hardware, the I'm software between to nanoparticle now becoming saw coordination accelerate elements. manufacturing last
experimental increasing enabled scale successfully has in us set As proteins of and the can we be model assay increase reported the to QX, robustness that decoded.
PRISM, be our the publicly frequently launch. XXXX, of large had of remain across estimate not and epitopes Coming additional validation exciting conversations following topics: how pipeline on of the proteins the increasing to our previously required scientific further detect event diverse where Overall, at protein focused run that implementation to we'll presenting to single the platform molecule multiple within a incredibly rate. our These of detail X pattern are model ability with single next the molecules include suggestions applications to technical to on flow platform, of of at involving the we updates for nano excited specific path computational in how false experimental application envisioned. on number we methods our on on about resolution, out weeks to multi-affinity large-scale are and and verification the experiments discovery progress sharing pro sharing mobilize progress mixes conference essential areas. of towards opportunities systems. underpinnings ranging and lead XXXX our on have to range probes These cell, and from data the elements them we broader have comes ready ongoing U.S. The demonstration into our to to the platform. objective to we We community our models concentrations our into we required to a our future Hupo continue diversified foundational complexity broader addressing and to with Portland, ideation at major in ensure and efforts launch of commitment for out the our that of we'll proteins reach instrument of are am the sharing proteomics proteomics numbers to customers an of excited of openness, to continue transition listen towards large cycles by ongoing community, across an and transparency on to creative further opportunity use.
In Oregon.
I the the
additional the in studies. the and targeted we've and studies we've platform targeted broad of been All for scale the sharing that One with studies towards advances synergistically and Genentech partnership has data of resulting for simultaneously our that about proteoform platform be areas the pursuing excited that is advanced Amgen. EGFR made we'll most I'm from our Tau advancing proteoform
biology a We heterogeneity the how proteoforms and from platform proteoforms, to at as variants and combination measure uniquely defined of by post-translational important continue [indiscernible] single splice excitement to is suited the our modifications, molecular about molecule of hear the community resolution.
work we is to it of have get where year confident of profound the Sujal Sujal. platform about As earlier, done we that, that back users, this eyed what the a impact.
With can foundational into come be hands turn a mentioned what have understanding our to and I'll into to remains call solid clear required
